电邮这篇文章 The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
- 作者: Mazurina N.V.1, Artamonova E.V.2, Beloyartseva M.F.2, Volkova E.I.3, Ganshina I.P.2, Troshina E.A.1, Tjulandin S.A.2, Chubenko V.A.4
-
隶属关系:
- Endocrinology Research Centre
- Blokhin National Medical Research Center of Oncology
- Loginov Moscow Clinical Scientific Center
- Saint Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological)
- 期: 卷 22, 编号 4 (2020)
- 页面: 56-59
- 栏目: CLINICAL ONCOLOGY
- URL: https://medbiosci.ru/1815-1434/article/view/61146
- DOI: https://doi.org/10.26442/18151434.2020.4.200566
- ID: 61146
如何引用文章
全文:
详细
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Association of Endocrinologists and the Russian Society of Clinical Oncology. The consensus contains recommendation on risk assessment, prophylaxis and correction of hyperglycemia regarding the baseline metabolic status of the patients.
作者简介
Natalya Mazurina
Endocrinology Research Centre
编辑信件的主要联系方式.
Email: natalyamazurina@mail.ru
ORCID iD: 0000-0001-8077-9381
D. Sci. (Med.)
俄罗斯联邦, MoscowElena Artamonova
Blokhin National Medical Research Center of Oncology
Email: artamonovae@mail.ru
ORCID iD: 0000-0001-7728-9533
D. Sci. (Med.), Prof.
俄罗斯联邦, MoscowMaria Beloyartseva
Blokhin National Medical Research Center of Oncology
Email: mfb1973@gmail.com
ORCID iD: 0000-0002-7897-3422
Cand. Sci. (Med.)
俄罗斯联邦, MoscowEkaterina Volkova
Loginov Moscow Clinical Scientific Center
Email: volkowa_endocrinology@mail.ru
ORCID iD: 0000-0003-3717-1148
endocrinologist
俄罗斯联邦, MoscowInna Ganshina
Blokhin National Medical Research Center of Oncology
Email: ganshinainna77@mail.ru
ORCID iD: 0000-0002-0105-9376
Cand. Sci. (Med.)
俄罗斯联邦, MoscowEkaterina Troshina
Endocrinology Research Centre
Email: troshina@inbox.ru
ORCID iD: 0000-0002-8520-8702
D. Sci. (Med.), Prof., Corr. Memb. RAS
俄罗斯联邦, MoscowSergey Tjulandin
Blokhin National Medical Research Center of Oncology
Email: clingen@mail.ru
ORCID iD: 0000-0001-9807-2229
D. Sci. (Med.), Prof.
俄罗斯联邦, MoscowViacheslav Chubenko
Saint Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological)
Email: vchubenko@me.com
ORCID iD: 0000-0001-6644-6687
Cand. Sci. (Med.)
俄罗斯联邦, Saint Petersburg参考
- Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли. 2020; 10 (3s2). https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-09.pdf [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical recommendations for drug treatment of breast cancer. Malignant Tumors. 2020; 10 (3s2). https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-09.pdf (in Russian).]
- Семиглазова Т.Ю., Семиглазов В.В., Клименко В.В. и др. Применение алпелисиба для лечения HR+ HER2-метастатического рака молочной железы у пациентов с мутацией PIK3CA: результаты исследования SOLAR-1. Фарматека. 2020; 27 (7): 15–23. doi: 10.18565/pharmateca.2020.7.15-23 [Semiglazova T.Iu., Semiglazov V.V., Klimenko V.V. et al. Primenenie alpelisiba dlia lecheniia HR+ HER2-metastaticheskogo raka molochnoi zhelezy u patsientov s mutatsiei PIK3CA: rezul’taty issledovaniia SOLAR-1. Farmateka. 2020; 27 (7): 15–23. doi: 10.18565/pharmateca.2020.7.15-23 (in Russian).]
- Andre F, Ciruelos E, Rubovszky G et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929–40. doi: 10.1056/NEJMoa1813904
- Rugo HS, André F, Yamashita T et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020; 31 (8): 1001–10. doi: 10.1016/j.annonc.2020.05.001
- Świderska E, Strycharz J, Wroblewski A et al. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake. 2018. doi: 10.5772/intechopen.80402
- Дедов И.И., Шестаков М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2019; 22 (1S1): 1–144. doi: 10.14341/DM221S1 [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Standards of specialized diabetes care. Diabetes mellitus. 2019; 22 (1S1): 1–144. doi: 10.14341/DM221S1 (in Russian).]
- Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Клинические рекомендации Российской ассоциации эндокринологов. Сахарный диабет 1 типа у взрослых. Сахарный диабет. 2020; 23 (S1). doi: 10.14341/DM23S1 [Dedov I.I., Shestakova M.V., Maiorov A.Iu. et al. Klinicheskie rekomendatsii Rossiiskoi assotsiatsii endokrinologov. Sakharnyi diabet 1 tipa u vzroslykh. Sakharnyi diabet. 2020; 23 (S1). doi: 10.14341/DM23S1 (in Russian).]
- Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Клинические рекомендации Российской ассоциации эндокринологов. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020; 23 (S2). doi: 10.14341/DM23S2 [Dedov I.I., Shestakova M.V., Maiorov A.Iu. et al. Klinicheskie rekomendatsii Rossiiskoi assotsiatsii endokrinologov. Sakharnyi diabet 2 tipa u vzroslykh. Sakharnyi diabet. 2020; 23 (S2). doi: 10.14341/DM23S2 (in Russian).]
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl. 1): S13–S28. doi: 10.2337/dc19-S002
- American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl. 1): S90–S102. doi: 10.2337/dc19-S009
- Classification of diabetes mellitus. World Health Organization, 2019. https://apps.who.int/iris/handle/10665/325182
- Davies MJ, D’Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–98. doi: 10.1007/s00125-018-4729-5/
- Инструкция по медицинскому применению препарата Пикрэй ЛП-006279 от 19.06.2020. [Instructions for medical use of the drug Pikray LP-006279 dated 06/19/2020 (in Russian).]
补充文件
